Grass Pollen Allergy Clinical Trial
Official title:
Safety and Dose Finding Study Based on the Effects of Three Subcutaneous Injections of BM32, a Recombinant Hypoallergenic Grass Pollen Vaccine, on Responses to Allergen Challenge by Skin Testing and in the Vienna Challenge Chamber (VCC) as Well as Immunological Response in Subjects Know to Suffer From Grass-pollen Induced Allergic Rhinitis
The study will evaluate the dose response of immunotherapy against grass pollen allergy
using the recombinant grass pollen vaccine BM32. Efficacy will be analyzed by:
- skin prick testing
- grass pollen inhalation challenge
- antibody responses. In addition, the safety of subcutaneous application of BM32 will be
evaluated.
n/a
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05560698 -
A Motivation-enhancing App to Retain Patients With Hay Fever in a Trial After Treatment
|
N/A | |
Completed |
NCT01830673 -
Regulatory T-cells After Subcutaneous Immunotherapy
|
N/A | |
Active, not recruiting |
NCT04502966 -
Grass Pollen Immunotherapy Plus Dupilumab for Tolerance Induction
|
Phase 2 | |
Completed |
NCT00263601 -
Safety and Efficacy of Grass Pollen Allergoid in the Treatment of Allergic Rhinoconjunctivitis
|
Phase 3 | |
Completed |
NCT01538979 -
Phase II Study of Grass Pollen Allergy Vaccine BM32
|
Phase 2 | |
Completed |
NCT04435678 -
Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens
|
N/A | |
Completed |
NCT00264459 -
Safety and Efficacy of a Sublingual Specific Immunotherapy With an Extract of a Six Grass Pollen Mixture
|
Phase 3 | |
Completed |
NCT01308021 -
Clinical Efficacy and Safety of gpASIT+TM to Treat Seasonal Allergic Rhinoconjunctivitis
|
Phase 2 | |
Completed |
NCT00773240 -
A Phase III Trial Assessing the Pharmacodynamic Effect and the Tolerability of Grazax Treatment
|
Phase 3 |